Company Summary - Dechra Pharmaceuticals PLC (LSE:DPH)
569.50p
9.50p
(-1.67%)
FTSE Small Cap Pharmaceuticals & BiotechnologyMarket cap: £380.380m
NEW Explore our new and improved report for Dechra Pharmaceuticals PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
International veterinary pharmaceutical business
| Financials - Annual Report (30/06/2011) | ||
|---|---|---|
| Turnover | £m | 389.24 |
| Pre-tax Profit | £m | 18.51 |
| EPS | p | 23.02 |
| DPS | p | 10.9 |
| Dividend Yield | % | 1.914 |
| Director | Board Role |
|---|---|
| Michael Redmond | Chairman |
| Ian Page | Chief Executive |
| Simon Evans | Finance Director |
Products Brands & Subsidiaries
Products & Brands
Dales; Dermatology; Endocrinology; Equine Medicine; FELIMAZOLE; Ophthalmology; SPECIFIC; VETORYL; Veterinary Products EU
Subsidiaries
Veneto Ltd; Anglian Pharma Ltd; Dechra Ltd; Dechra Veterinary Products LLC; Dechra Investments Ltd; Dechra Veterinary Products SAS...
Broker Sentiment (9 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Product Acquisition HY-50® | 31/01/2012 |
| Trading Update | 11/01/2012 |
| Total Voting Rights | 30/12/2011 |
For more information
and investor relations, visit the
Dechra Pharmaceuticals PLC company website: